Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity

Trial Profile

Study of SOM0226 in Familial Amyloid Polyneuropathy (FAP) Patients and Asymptomatic Carriers to Evaluate Protein Stabilization Activity

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Tolcapone (Primary)
  • Indications Amyloid polyneuropathy
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors SOM Biotech
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Nov 2016 Status changed from recruiting to completed.
    • 21 Apr 2016 Results of Phase IIa part (n=21) presented at the 68th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top